Novo Nordisk's Research Calendar: CagriSema Data, a Washington Congress and the 4 November Print
Published on 10/30/2026 at 09:11 | Editorial boerse-global.de
Novo Nordisk has spent the past week stacking up scientific presentations on both sides of the Atlantic, and investors now face a scheduling question as much as a scientific one. Two retrospective analyses of the REDEFINE 1 trial, released on 20 October and presented at the annual meeting of the Menopause Society, sit alongside 26 abstracts slated for ObesityWeek in Washington from 14 to 17 November. A further twelve contributions are earmarked for The Liver Meeting in Denver between 5 and 9 November. Before any of that lands, however, the Danish drugmaker reports results for the first nine months of 2026 on 4 November.
The order matters. The financial release speaks to commercial momentum; the congresses speak to the state of the science. Neither substitutes for the other, and the volume of abstracts on its own says nothing about their economic weight or their consequences for revenue.
What the CagriSema Readout Actually Shows
The REDEFINE 1 analyses covered 2,309 women and examined weight loss under CagriSema. According to the company, average weight reduction reached 25.0% after 68 weeks, against 3.0% on placebo — figures that assume the treatment was adhered to as prescribed. Two caveats belong to that result rather than sitting outside it: the analysis was retrospective, and it was confined to women. Anyone reading only the headline number is leaving out part of the finding.
That is why the central question for shareholders is not simply whether CagriSema produces a pronounced effect. It is whether further results reinforce the finding convincingly enough to support a broader judgement on the obesity portfolio. A single strong headline carries less weight than a consistent clinical picture.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Lilly's Shadow and the Limits of Comparison
Competitive pressure remains the counterargument that will not go away. Eli Lilly reported that Retatrutide, in the Phase III TRANSCEND-T2D-2 study, delivered stronger improvements in blood sugar and weight than Ozempic after 80 weeks — a result that raises the stakes for Novo Nordisk's GLP-1 franchise.
The comparison, though, involves Ozempic, not CagriSema. It does not overturn the positive CagriSema findings, and those findings in turn say nothing about how the drug stacks up against Retatrutide. Folding results from different compounds into a single verdict on competitiveness would be a risky exercise. The shares added 2.2% yesterday, a move that cannot be pinned cleanly to any one clinical announcement.
Two Congresses, Two Agendas
ObesityWeek will centre on the obesity portfolio and on real-world treatment experience, including everyday data on the Wegovy tablet and its injectable form, fresh CagriSema analyses, and studies of semaglutide in children aged six to under twelve. The Liver Meeting shifts the focus to semaglutide and the investigational drug Efruxifermin, with real-world semaglutide data and research into the liver disease known as MASH among the topics.
Both are presentation programmes — not clinical wins already banked, and not regulatory progress. The distinction between a development candidate and a marketed product matters here: real-world data answer different questions than controlled clinical programmes do, and no efficacy edge can be inferred from an announcement alone. The tablet experience in particular turns attention to how treatment performs outside the controlled trial setting.
The Bull and Bear Cases in Brief
If the Washington and Denver presentations complement the existing evidence persuasively, investor attention could shift toward Novo Nordisk's own pipeline rather than fixating on news about rival compounds. Disappointment, by contrast, would let competitive pressure weigh more heavily — especially if shareholders have already drawn broader conclusions from the retrospective CagriSema analysis than its scope permits.
What emerges from the individual contributions will decide the matter, not how many of them there are.
Ad
Novo Nordisk Stock: New Analysis - 30 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
